Introduction
In the 1950s, after the role of dopamine (DA) as a signaling molecule in the brain was demonstrated, 1 it was reported that DA levels dramatically decrease in Parkinson's disease (PD). 2 Shortly after that, the DA precursor l-DOPA (l-3,4-dihydroxyphenylalanine) was started to be used to increase DA concentration in the brain of patients with PD. 2 The temporary relief of PD symptoms by l-DOPA indicated that loss of DA signaling is the pathognomonic feature of PD. Evidence from animal models and humans has shown that, in addition to PD, DA signaling also plays a central role in several brain disorders including schizophrenia, essential tremor, attention deficit hyperactivity disorder, depression, and addiction. This plethora of DA-associated diseases closely matches with the function of the DA system in multiple brain functions such as motor coordination, emotions, memory, reward mechanisms, and neuroendocrine regulation. The brain DA system is constituted by DA-containing nuclei (i.e., substance nigra pars compacta, ventral tegmental area, and arcuate nucleus) and by the target areas (i.e., cortex, basal ganglia, thalamus, limbic structures, and pituitary gland). 1 On target areas, DA acts through five DA receptors, which belong to the superfamily of seven-transmembrane G proteincoupled receptors (GPCRs). Based on structural, biochemical, and pharmacologic criteria, DA receptors have been grouped into two main families: the D 1 3 R has a distinctive third intracellular loop. 3 A growing body of evidence suggests that aberrant D 3 R signaling contributes to several brain disorders. Consequently, D 3 R has emerged as a potential therapeutic target in the treatment of major neurological disorders such as schizophrenia, 4 PD, 5 and addiction. However, the mechanisms underlying D 3 R signaling are poorly understood, either in healthy or diseased brain. Here, I review recent reports on the molecular mechanisms involved in D 3 R signaling via monomeric D 3 R and heteromeric receptor complexes. Then, I illustrate examples of qualitative and quantitative changes in D 3 R signaling that may contribute to several brain diseases. I conclude with a description of potential targets for the modulation of D 3 R signaling. Unraveling the unknown downstream signaling pathways activated by D 3 R in both the healthy and the diseased brain is likely to reveal new therapeutic strategies toward DA-associated disorders.
Monomeric and Heteromeric D 3 R Signaling
Brain D 3 R messenger RNA (mRNA) is detected early in development (e.g., in the embryonic days 10 and 11 of rodents) 6 and continually expressed during the postnatal 2 Journal of Central Nervous System Disease period. [7] [8] [9] [10] In adult rats 11 and mice, 12 regions that affect emotional, cognitive, and endocrine functions express D 3 R mRNA (e.g., nucleus accumbens, islands of Calleja, hippocampus, prefrontal cortex, hypothalamus, and striatum). Interestingly, in the mouse brain, the D 3 R co-expressed with D 1 R and D 2 R with regional, sex, and age-dependent differences in the coexpression pattern. 12 In the human brain, D 3 R mRNA has been detected in nucleus accumbens and in the islands of Calleja. 13 Although D 3 R is widely expressed in the brain, elucidating D 3 R signal transduction mechanisms has been challenging because D 3 R and D 2 R have similar pharmacologic profiles due to the high sequence identity and homology shared by these receptors (e.g., homology of 52% overall and of 75% in the transmembrane domain of rat sequences). 11 To specifically activate D 3 R, many studies have been performed in heterologous expression systems. These experimental systems have revealed that D 3 R can be linked to a wide array of intracellular signals via its coupling to multiple G protein α subunits, such as G iα3 , 14 G o , 15, 16 G q , 17, 18 and G s . 19 Consistent with its ability to activate multiple G proteins, D 3 R can modulate several downstream effectors including adenylyl cyclase, cyclindependent kinase 5 (CDK5), creatine kinase 1 (CK-1), protein kinase A (PKA), protein kinase B (PKB)/Akt, protein kinase C (PKC), phospholipase C (PLC), phospholipase D (PLD), protein phosphatase 2B (PP2B), and extracellular signal-regulated kinase (ERK). [14] [15] [16] 18, [20] [21] [22] [23] [24] [25] [26] [27] Moreover, under particular conditions, D 3 R can mediate both opposite and synergistic interactions with signaling pathways related to the production of cyclic adenosine monophosphate (cAMP). 21 Despite having similar sequences and pharmacologic profiles, D 3 R and D 2 R exhibit significant biochemical differences. For instance, D 2 R activates ERK via a G iα -dependent pathway, whereas D 3 R activates ERK by a mechanism that depends on G βγ . 26 In addition to the canonical signaling via monomeric GPCRs, several reports indicate that the interaction among GPCRs (forming dimers and higher-order entities) can influence GPCR signaling both quantitatively (i.e., heteromers exhibit increased affinity for the ligand) and qualitatively (i.e., heteromers use alternative signaling pathways). 28 33 and nicotinic acetylcholine receptors. 34 The D 3 R-D 1 R interaction increases the affinity of D 1 R for its ligand after D 3 R activation, whereas no change is observed in the D 3 R affinity to its ligand. 31 The activation of A 2a R in the D 3 R-A 2a R macromolecular complex reduces both the affinity of D 3 R for DA and the D 3 R-mediated inhibition of adenylate cyclase, whereas A 2a R signaling is inhibited by D 3 R activation. 30 Moreover, D 3 R interacts with its own alternatively spliced variant, named D 3 nf, as demonstrated by coimmunoprecipitation and colocalization experiments. [35] [36] [37] The expression of D 3 nf reduces the ligand-binding capacity of D 3 R, possibly due to D 3 R-D 3 nf mislocalization from the plasma membrane to intracellular compartments. 37 The D 3 R gene contains 6 exons and 5 introns and produces at least 7 distinct alternatively spliced variants including the full-length D 3 R, a shorter receptor isoform (D 3 S) lacking 21 amino acids within the third intracellular loop (IL 3 ), and the truncated isoform D 3 nf lacking transmembrane-spanning domains 6 and 7 by a premature stop codon. 38 Interestingly, D 3 R and D 3 S bind DA with high affinity, whereas the 5 additional D 3 R variants including D 3 nf do not bind DA, but they may regulate receptor dimerization. 39 Overall, this evidence supports the idea that receptor-receptor interactions at neuronal surface modulate D 3 R signaling.
Multiple D 3 R-associated pathways have been described in neurons. 22, 27 Indeed, D 3 R can modulate neural activity by acting on neurotransmitter receptors via PKA, as well as on ion channels via G αi/o , as demonstrated by electrophysiological and imaging studies in isolated neurons and brain slices from rodents. 17, [40] [41] [42] These studies, however, did not clarify whether D 3 R effects are mediated by monomeric-canonical pathways or by heteromeric receptors. In medium spiny neurons (MSNs) of the striatum, D 3 R modulates Ca 2+ channels via PLC and PP2B 43 and can also activate the Akt/ mTOR/p70S6/4E-BP1 pathway, 44 which play a key role in protein synthesis, synaptic plasticity, and memory. Also, D 3 R suppresses synaptic transmission by reducing GABA A receptor current via PKA-mediated endocytosis of GABA A receptors in the nucleus accumbens 40 and in CA1 pyramidal neurons from the hippocampus. 41 Actions of D 3 R in the brain might be region specific 7 and may be quantitative and qualitatively modified under disease states, as discussed in the following sections.
D 3 R Signaling in Brain Diseases

Essential tremor
A critical insight into the role of D 3 R signaling in brain dysfunction was provided by studying the D 3 R Ser9Gly polymorphism in patients with essential tremor, the most commonly inherited movement disorder. In essential tremor, a subtle change in the D 3 R sequence (Ser9Gly polymorphism) increases D 3 R coupling to both the inhibition of cAMP formation and the activation of the MAPK pathway ( Figure 1A ). The enhanced D 3 R function, associated with the Gly-9 variant, was linked with the risk and age at onset for essential tremor. 45 Further supporting the primary role of the gain of function of D 3 R in pathological DA signaling, the D 3 R-Gly-9 variant has been associated with impulsive behavior in PD, the second most prevalent neurodegenerative disease. Thus, these data suggest that an enhanced D 3 R signaling could impair reward-risk assessment in the mesolimbic system and contribute to the development of impulsive behavior, in carriers of this genotype. Overall, these data suggest that a gain of function in two D 3 R signaling pathways significantly contributes to brain dysfunction. It is noteworthy that the association of the D 3 R Ser9Gly polymorphism with essential Prieto 3 tremor has been found to be significant in American, French, 45 and Spanish 46 but not in Italian 47 or Asian 48 populations.
Parkinson's disease
Supporting the idea that a gain of function of D 3 R can impair brain physiology, recent evidence suggests that D 3 R activity is enhanced in PD, 43 ,49 a neurodegenerative disease characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Loss of dopaminergic neurons is accompanied by a dramatic reduction in DA levels in the striatum. [50] [51] [52] Several reports have shown that DA depletion induces compensatory mechanisms (e.g., an increase in the number and the affinity of receptors), similar to that observed after ligand depletion in other receptor-ligand systems. 53, 54 For instance, positron emission tomography using [ 11 C]raclopride has shown an increased density of D 2 -class receptors in the putamen nucleus in PD. 55 Also, biochemical, electrophysiological, 
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Journal of Central Nervous System Disease and behavioral data have shown that DA depletion increases the sensitivity (supersensitivity) of D 2 -class receptors in animals models of PD (e.g., DA depletion induced by reserpine, 56 α-methyl-p-tyrosine, 57 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
[MPTP], 58 and 6-hydroxydopamine [6-OHDA]). 49, 59, 60 In the 6-OHDA model, electrophysiological recordings in striatal MSNs have shown that D 3 R signaling contributes to the D 2 -class supersensitivity, 43, 49 thus suggesting that DA depletion may increase D 3 R expression and activity.
The enhancement of D 3 R signaling by DA depletion may be reflecting changes in pharmacologic parameters (potency, affinity, and receptor number). At present, however, there is no consensus on which pharmacologic parameter is mainly affected. 10, 11, [61] [62] [63] [64] Although unilateral lesion of the substantia nigra with 6-OHDA increases the potency of the selective D 3 R agonist 7-OH-DPAT in striatum 65 and cerebellum, 66 pharmacologic depletion of catecholamines increases the affinity of putative D 3 sites with no increase in the total number of sites in striatum. 67 An alternative mechanism underlying the enhancement of D 3 R signaling following DA depletion may rely on a reduced interaction of D 3 R with its regulatory splice variant D 3 nf. Indeed, D 3 nf protein levels were found to be reduced in striatal homogenates from 6-OHDA lesioned rats. 43 In line with a reduction in D 3 R-D 3 nf interaction after DA depletion, the D 3 R/D 3 nf mRNA ratio increases when D 3 R is pharmacologically blocked (i.e., mimicking "hypodopaminergic" states). 68 According to recent reports, qualitative changes in D 3 R signaling may also contribute to the pathophysiology of PD. In particular, a switch in D 3 R signaling has been described in striatal MSNs and striatonigral terminals of hemiparkinsonian rats, 43 ,69 a PD model based on the 6-OHDA-mediated lesion of substantia nigra pars compacta in one hemisphere. In striatal MSNs, while physiological D 3 R signaling inhibits Ca V 1 (L-type) Ca 2+ channels by PP2B activation, D 3 R additionally modulates Ca V 2.1 (P/Q-type) channels via the hydrolysis of phosphatidylinositol-4,5-biphosphate (PIP 2 ) after DA depletion ( Figure 1B ). This Ca V 2.1 modulation by the D 3 R-PIP 2 pathway is not detected in neurons from control animals, thus suggesting that this pathway is induced by DA depletion. 43 Because Ca V 2.1 channels mediate γ-aminobutyric acid (GABA) release from the terminals of striatal neurons, the PIP 2 -dependent D 3 R signaling may reduce GABA release and affect synaptic transmission between striatal neurons after DA depletion.
In striatonigral terminals, the switch in D 3 R signaling is related to the D 3 R-D 1 R interaction. 69 Although D 3 R activation potentiates both the stimulation of GABA release and the production of cAMP by D 1 R in terminals from the control (nonlesioned) hemisphere, D 3 R inhibited both D 1 R actions in terminals from the denervated hemisphere. 69 Overall, data from MSNs and striatonigral terminals support the notion that DA depletion switches D 3 R signaling in basal ganglia. l-DOPA, the gold standard treatment for PD, reduces parkinsonian symptoms but in later stages induces dyskinesia, a side effect characterized by hyperkinetic involuntary movements. 70 Notably, l-DOPA increases D 3 R expression in the caudate/putamen nuclei and striatonigral MSNs. 62, 63, [71] [72] [73] Recent evidence indicates that D 3 R plays a major role in l-DOPA-induced dyskinesia, which can be reduced by blocking D 3 R 73-75 and D 1 R 75 in parkinsonian models. Interestingly, in MPTP parkinsonian primates, a partial block of D 3 R (using a partial agonist for D 3 R) reduces dyskinesia without affecting the therapeutic effects of l-DOPA, whereas no recovery of motor disturbances is observed if D 3 R is entirely blocked. 74 These data emphasize that D 3 R mediates different actions, participating in both dyskinesia and motor recovery following l-DOPA treatment, thus highlighting the importance of finetuning D 3 R signals in PD-diseased brain.
Schizophrenia
Dopamine signaling is the main target in schizophrenia, a mental disorder characterized by hallucinations, bizarre delusions, and negative symptoms such as lack of motivation, reduction in spontaneous speech, and social withdrawal. Indeed, first-generation antipsychotics (e.g., haloperidol and chlorpromazine) bind to D 2 -class receptors. 76, 77 Since its cloning in 1990, D 3 R emerged as a potential target for antipsychotics. 11, 78 Although it is controversial whether D 3 R levels are affected in schizophrenia, 79 postmortem studies suggest that D 3 R levels may be elevated in people with schizophrenia who are off antipsychotics ( Figure 1C) . 4 In contrast, the parietal cortex of postmortem tissue from long-term hospitalized patients with chronic schizophrenia expresses low D 3 R levels. 80 These data suggest that long-term antipsychotic medication may modify brain D 3 R expression in schizophrenia. Interestingly, low D 3 R mRNA levels in patients with schizophrenia have been associated with an enhanced D 3 nf-specific splicing of D 3 R pre-mRNA. 81 
Addiction
Chronic drug use induces long-lasting neuroadaptations which has been associated with dopaminergic abnormalities. Although studies of D 3 R expression in human cocaine-dependent subjects have had conflicting results, 39 the use of the D 3 Rpreferring radioligand [ 11 C](+)PHNO has shown higher number of available D 3 R in the substantia nigra, hypothalamus, and amygdala of cocaine addicts, compared with healthy controls 82 ( Figure 1D) . Notably, substantia nigra D 3 R levels correlated with years of cocaine use. 82 Consistent with the idea that chronic cocaine exposure leads to adaptive increases in D 3 R expression, a 6-fold increase in D 3 R mRNA levels was found in the nucleus accumbens of cocaine overdose victims, as compared with age-matched and drug-free control subjects. 83 Similarly, an increased [ 11 C](+)PHNO binding, reflecting
higher D 3 R levels, has also been observed in the substantia nigra of methamphetamine users, 84 as well as in hypothalamus of alcohol-dependent patients. 85 According to the heightened D 3 R signaling in drug users, the functionally enhanced D 3 RGly-9 variant was associated with the development of earlyonset heroin dependence in Chinese population ( Figure 1D ). 86 Studies in vitro and in animal models support the idea that drug use induces D 3 R signaling abnormalities. In vitro, cocaine increases dendritic arborization and soma area in cultured dopaminergic neurons from mouse via D 3 R-dependent activation of ERK and Akt. 87 In rats, it has been suggested that D 3 R play an important role in mediating nicotine's effects on the brain. 88 In both adolescents and adult rats, nicotine upregulates D 3 R but reduces D 3 nf mRNA levels in the nucleus accumbens, thus increasing the D 3 R/D 3 nf ratio ( Figure 1D) . 88 It has also been proposed that D 3 R and its alternatively spliced isoform D 3 nf may play a role in cocaine addiction (a risk factor for schizophrenia) and behavioral sensitization (the progressive and long-lasting augmentation of certain behaviors following repetitive stimulant drug administration). 39 Supporting this idea, D 3 R has been found to enhance the reinforcing effect of cocaine, 89 and blockade of D 3 Rs inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats. 90 A cornerstone study demonstrated the crucial role of D 3 R signaling in the motivation to take drug induced by drug-related cues. 91 In this study, rats were trained to self-administer cocaine by a lever pressing. Next, progressively, a light stimulus was associated with cocaine self-administration. Light stimulus, which then becomes the conditioned stimulus, gains reinforcing properties and finally maintains drug-seeking behavior even without drug delivery. Remarkably, the selective D 3 R partial agonist BP897 dose-dependently reduced cue-induced cocaine-seeking behavior in rats trained under this schedule of reinforcement. 91 Overall, multiple lines of evidence support the idea that D 3 R plays a central role in addiction, thus driving a need to develop novel pharmacologic agents targeting this receptor. Since 2005, 110 patents or patent applications have been published on original compounds with D 3 R selectivity. 79 In contrast to the initial lack of D 3 R-selective drugs, a list of compounds with relative high selectivity for D 3 R currently includes the following: BP 897, SB-277011A, S33084, ABT-925, GSK598809, and F17141. 79 In particular, GSK598809 has proven to transiently alleviate craving in smokers after overnight abstinence, thus providing the first clinical evidence for a usefulness of D 3 R antagonist for the treatment of addiction. 92 Emerging perspectives for improving the treatment of brain disorders focus on the understanding of pathophysiology mechanisms to identify disease pathways, which will finally facilitate the selection of therapeutic targets. 93 In DA-related brain diseases, quantitative and qualitative changes in D 3 R signaling may be reflecting direct effects on basic mechanisms that control D 3 R activity at the cell surface, such as desensitization and internalization. A better understanding of these basic mechanisms in both the healthy and the diseased brain is likely to reveal new molecular targets for therapeutic.
Modulation of D 3 R Signaling
Dopamine receptors are modulated by several mechanisms, such as homologous and heterologous desensitization, a reversible reduction in signal transduction after acute activation. Experimental and theoretical data suggest that D 3 R desensitization (tolerance) can develop after its structural rearrangement following agonist binding, and that the magnitude of the second D 3 R response can be reduced by 60% compared with the first response. 94 Also, D 3 R can be desensitized following phosphorylation by both PKC 95 and Ca 2+ /calmodulin-dependent protein kinase II (CaMKII). 96 Both PKC and CaMKII phosphorylate the 229-serine residue at the IL 3 , a region that exhibits high divergence between D 2 R and D 3 R, and may play a crucial role in the unique signaling signatures of each receptor subtype. 97 Downregulation of D 3 R signaling by CaMKII depends on intracellular Ca 2+ levels and, therefore, is associated with neuronal activity. 96 Importantly, the CaMKII-mediated inhibition of D 3 R is not observed after DA depletion. 69 Although D 3 R undergoes limited agonist-induced internalization, 98 D 1 R-D 3 R heterodimers can be internalized in response to the paired stimulation of both D 1 R and D 3 R via a β-arrestin-dependent mechanism in human embryonic kidney 293 cells. 32 Also, a recent report showed that PKC-mediated phosphorylation of D 3 R can induce clathrin-mediated D 3 R endocytosis and lysosomal D 3 R degradation. 95 Similarly, via caveolin/clathrin-mediated D 3 R internalization, dysbindin-1 reduces the magnitude and potency of DA-induced cAMP production and phosphorylation of ERK1/2 and Akt. 99 Notably, dysbindin-1 is a candidate gene for schizophrenia. Palmitoylation is another posttranslational modification that can regulate D 3 R activity. Compared with D 2 R, D 3 R undergoes a more extensive palmitoylation on its cysteine residues at the carboxyl terminus tail and, importantly, palmitoylation was found to be essential for cell surface expression, PKC-mediated endocytosis, agonist affinity, and agonist-induced tolerance of D 3 R. 100 Also, DA receptor-interacting proteins, such as AIP1 (ALG-2 interacting protein 1) could be substantial in D 3 R stability and trafficking. 101 
Concluding Remarks and Perspectives
In the past few years, great progress has been made in understanding D 3 R signaling in heterologous systems. Although neural D 3 R signaling is incompletely understood, a growing body of evidence indicates that changes in D 3 R-induced pathways contribute to several neurological disorders. Future studies may delineate the relative contribution of monomeric-canonical versus heteomeric D 3 R signaling to pathological brain states. Another intriguing aspect that remains to be clarified is whether sex-specific differences influence D 3 R signaling in the diseased brain, as suggested by the association of the Gly allele of the D 3 R Ser9Gly polymorphism with schizophrenia in female but not male patients. 102, 103 According to several reports, changes in both D 3 R signaling and DA levels are common factors in PD and schizophrenia. Similarly, quantitative and qualitative changes in D 3 R signaling develop after DA depletion in the 6-OHDA hemiparkinsonian model. 43, 69 However, it remains to be clarified whether the altered D 3 R signaling is reflecting an adaptive mechanism to compensate changes in DA levels. Some properties of D 3 R strongly suggest that D 3 R is the main detector of changes in extracellular DA concentration and, consequently, D 3 R signaling may be mainly affected by pathological changes in DA levels, as those observed in PD and schizophrenia. In particular, presynaptic and postsynaptic sites can contain D 3 R, 104, 105 which exhibits high affinity for DA (~25 nM). 11, 97, 106 Considering basal extracellular (5-10 nM) and synaptic (50 nM) concentrations of DA, [107] [108] [109] [110] a fraction of D 3 R may be constitutively activated, thus playing a crucial role in both tonic and phasic DA signaling. 67 Interestingly, the occupancy of D 3 R by DA is not completely abolished by catecholamine depletion using reserpine, 67, 111 suggesting that even under severe reduction in DA level, D 3 R is partially activated and able to perceive changes in DA concentration. Thus, a tempting but simplified model for PD may rely on an enhancement in striatal D 3 R signaling as part of an adaptive mechanism to compensate the dramatic reduction in DA levels.
Although there is a clear role of D 3 R signaling in drugseeking behaviors and relapse in animal models, it is uncertain whether these findings translate to humans. Studies in humans could evaluate the significance of D 3 R signaling in neurological diseases. However, direct evidence of molecular mechanisms in the human brain has been elusive, primarily due to methodological limitations. Notably, novel approaches allow the study of functional responses, including receptor signaling, in postmortem human tissue. 112, 113 Using these novel approaches directly in human brain tissue, future studies will help to identify mechanisms that underlie pathological D 3 R signaling, either induced by quantitative or qualitative changes.
In summary, many brain disorders are characterized by perturbations in D 3 R signaling. A better understanding of how D 3 R activity can be regulated may uncover causal factors and may even suggest novel treatments for DA-related diseases. In particular, elucidating the mechanisms that control expression, desensitization, and alternative splicing of D 3 R may identify novel opportunities to modulate D 3 R signaling.
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